Zhejiang Cancer Hospital
🇨🇳China
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT04506138
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
A Clinical Study of Exploring Camrelizumab in the Treatment of Colorectal Mucinous Adenocarcinoma(MAC)
Phase 1
- Conditions
- Colorectal Cancer
- Interventions
- Drug: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)+IrinotecanDrug: Carilizumab + anti-angiogenic TKIs (available with fuquitinib, rigofenib, apatinib, etc.)
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2020-06-24
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04446091
- Locations
- 🇨🇳
Zhejiang Province Cancer Hospital, Hangzhou, Zhejiang, China
The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT04415385
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Rituximab Combined With Chidamide and Lenalidomide for r/r AITL
Not Applicable
- Conditions
- Angioimmunoblastic T-cell LymphomaChemotherapeutic ToxicityChemotherapy Effect
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT04319601
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Anlotinib in Combination With PD1 With Gemcitabine Plus(+)Cisplatin for Unresectable or Metastatic Biliary Tract Cancer
Phase 2
- Conditions
- Biliary Tract Cancer
- Interventions
- First Posted Date
- 2020-03-09
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04300959
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Camrelizumab Combined With Local Treatment in NSCLC Patients With BM
Phase 2
- Conditions
- NSCLC Stage IVBrain MetastasesImmunotherapy
- Interventions
- Drug: ImmunotherapyRadiation: WBRTDrug: Chemotherapy
- First Posted Date
- 2020-03-02
- Last Posted Date
- 2021-09-10
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT04291092
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Other: nonIntervention
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 237
- Registration Number
- NCT04266691
Correlation Between Molecular Typing and Neoadjuvant Chemotherapy in Breast Cancer Patients Based on Mammaprint/Blueprint Test
- Conditions
- Evaluation of the Value of Mammaprint Test Gene Variation in the Prediction of Neoadjuvant Chemotherapy for Breast Cancer
- Interventions
- Combination Product: neoadjuvant chemotherapy
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT04264468
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
Phase 2
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Drug: the first line chemotherapy for metastatic NSCLCRadiation: stereotactic body radiotherapy (SBRT)
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 35
- Registration Number
- NCT04255836
Preoperative Systemic Therapy vs Upfront Surgery in HER2 Positive Early Breast Cancer
Completed
- Conditions
- Breast CancerHER2Preoperative Systemic Treatment
- Interventions
- Procedure: Preoperative systemic treatment
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 1067
- Registration Number
- NCT04249440
© Copyright 2025. All Rights Reserved by MedPath